Association of cyclooxygenase-2 genetic variant with cardiovascular disease

European Heart Journal

Volumn 35, Issue 33, 2014, Pages 2242-2248

  Ross, Stephanie ^a,b   Eikelboom, John ^a   Anand, Sonia S ^a,b   Eriksson, Niclas ^c   Gerstein, Hertzel C ^a   Mehta, Shamir ^a   Connolly, Stuart J ^a   Rose, Lynda ^d   Ridker, Paul M ^d,e   Wallentin, Lars ^c   Chasman, Daniel I ^d,e   Yusuf, Salim ^a   Paré, Guillaume ^a,b,f  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UPPSALA UNIVERSITY   (Sweden)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Aspirin; Genetics; Myocardial infarction; Pharmacogenetics; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTACYCLIN; THROMBOXANE; 11-DEHYDRO-THROMBOXANE B2; 2,3-DINOR-6-KETOPROSTAGLANDIN F1ALPHA; 6 OXOPROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; THROMBOXANE B2;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEART INFARCTION; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; MULTICENTER STUDY (TOPIC); MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; URINE;

6-KETOPROSTAGLANDIN F1 ALPHA; AGED; ASPIRIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; FEMALE; HETEROZYGOTE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOXANE B2;

EID: 84908531195     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu168     Document Type: Article

References (35)

1. Fritsche E, Baek SJ, King LM, ZeldinDC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 2001;299:468-476.
2. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-617.
3. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.NEngl JMed1984;310: 1065-1068.
4. Hui Y, Ricciotti E, Crichton I, Yu Z, Wang D, Stubbe J, Wang M, Pure E, FitzGerald GA. Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation 2010;121:2654-2660.
5. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I,WuW, Pure E, Funk CD, FitzGerald GA. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 2012;4:132ra54.
6. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:1302-1308.
7. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.
8. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP,Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141: e89S-119S.
9. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221-2228.
10. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008;83:52-60.
11. Lemaitre RN, Rice K, Marciante K, Bis JC, Lumley TS, Wiggins KL, Smith NL, Heckbert SR, Psaty BM. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 2009;204:e58-e63.
12. Colaizzo D, Fofi L, Tiscia G, Guglielmi R, Cocomazzi N, Prencipe M, Margaglione M, Toni D. TheCOX-2G/C-765 polymorphism maymodulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis 2006;17:93-96.
13. Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, Jensen MK, Schmidt EB, Andersen PS, Overvad K. Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis 2010; 209:155-162.
14. Maguire J, Thakkinstian A, Levi C, Lincz L, Bisset L, Sturm J, Scott R, Whyte S, Attia J. Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome: a novel finding. J Stroke Cerebrovasc Dis 2011;20: 134-144.
15. Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, Roncal C, Paramo JA. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta 2006;368:138-143.
16. Lahteela K, Kunnas T, Lyytikainen LP, Mononen N, Taittonen L, Laitinen T, Kettunen J, Juonala M, Hutri-Kahonen N, Kahonen M, Viikari JS, Raitakari OT, Lehtimaki T, Nikkari ST.No association of nineteen COX-2 gene variants to preclinical markers of atherosclerosis The Cardiovascular Risk in Young Finns Study. BMC Med Genet 2012;13:32.
17. Montali A, Barilla F, Tanzilli G, Vestri A, Fraioli A, Gaudio C, Martino F, Mezzetti A, Cipollone F, Arca M. Functional rs20417 SNP (-765G.C) of cyclooxygenase-2 gene does not predict the risk of recurrence of ischemic events in coronary patients: results of a 7-year prospective study. Cardiology 2010;115:236-242.
18. Sharma V, Kaul S, Al-Hazzani A, Alshatwi AA, Jyothy A, Munshi A. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis 2013;35:95-99.
19. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22:1631-1636.
20. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078.
21. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
22. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368: 1096-1105.
23. Anand SS, Dagenais GR, Mohan V, Diaz R, Probstfield J, Freeman R, Shaw J, Lanas F, Avezum A, Budaj A, Jung H, Desai D, Bosch J, Yusuf S, Gerstein HC. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 2012;19:755-764.
24. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD,Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
26. Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, Buring JE. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy American women. Clin Chem 2008;54:249-255.
27. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.Arandomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
28. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952.
29. Reilly MP, LiM, He J, Ferguson JF, Stylianou IM, MehtaNN, Burnett MS, Devaney JM, KnouffCW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011;377:383-392.
30. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-1860.
31. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-360.
32. Martinez-Gonzalez J, Escudero I, Badimon L. Simvastatin potenciates PGI(2) release induced byHDLin human VSMC: effect on Cox-2 up-regulation andMAPKsignalling pathways activated by HDL. Atherosclerosis 2004;174:305-313.
33. NorataGD, Callegari E, Inoue H, Catapano AL.HDL3induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CREdependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004;24:871-877.
34. Liu D, Ji L, Tong X, Pan B, Han JY, Huang Y, Chen YE, Pennathur S, Zhang Y, Zheng L. Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. Am J Physiol Cell Physiol 2011;301:C739-C748.
35. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, NickersonDA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74:106-120.